Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Organigram Global Inc. (OGI) vs Sofgen Pharma S.A (PROCF)

Organigram Global Inc. and Sofgen Pharma S.A are both Drug Manufacturers Specialty & Generic companies. Organigram Global Inc. is the larger, with a market value of $155.1M against $114.0M — 1.4× the size. Sofgen Pharma S.A has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.4×. Organigram Global Inc. grew revenue faster over the last twelve months: 39.5% against 5.10%. Organigram Global Inc. has the higher net margin (28.4% vs 9.52%) and the lower return on invested capital (−1.53% vs 15.2%). Across the 17 metrics below, Organigram Global Inc. leads on 10 and Sofgen Pharma S.A on 7.

Valuation

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
P/E 2.37 n/m 20.14
P/S 0.67 n/m 2.25
P/B 0.42 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 16.79 3.29 12.29
EV/Sales 0.70 0.70 2.56
Earnings yield 42.26% 0.00% (2.99%)
Free cash flow yield (14.22%) 0.00% 0.00%

Profitability

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
Gross margin 36.47% 56.16% 53.94%
Operating margin (3.91%) 17.01% 0.00%
Net margin 28.44% 9.52% 0.00%
Free cash flow margin (9.46%) 17.66% 0.00%
Return on equity 20.20% (213.06%) (0.40%)
Return on assets 12.70% 8.82% (3.32%)
Return on invested capital (1.53%) 15.21% 0.00%

Growth

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 39.51% 5.10% 10.01%
EPS growth (last fiscal year) 60.00% (270.30%) —
Revenue growth, 5-year CAGR 24.30% (1.82%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
Debt to equity 0.04 (435.78) 0.05
Current ratio 2.61 0.64 2.31
Net debt to EBITDA (31.56) (7.21) 0.85

Dividend

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric OGI PROCF Drug Manufacturers Specialty & Generic median
Market cap 155.11m 113.95m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack